Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells

被引:121
作者
Levy, Ofer
Suter, Eugenie E.
Miller, Richard L.
Wessels, Michael R.
机构
[1] Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA
[2] 3M Pharmaceut, St Paul, MN USA
[3] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
D O I
10.1182/blood-2005-12-4821
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Newborns are prone to microbial infection and have poor memory responses to multiple antigens. We have previously shown that human neonatal blood monocytes exhibit impaired TNIF-alpha responses to most known TLR agonists, including the pure TLR7 agonist imiquimod. Surprisingly, however, neonatal TNF-alpha responses to the imiquimod congener R-848 (TLR 7/8) were fully intact. We now show that TLR8 agonists, including R-848 (TLR7/8), the imiclazoquinoline congeners 3M-003 (TLR7/8) and 3M-002 (TLR8), as well as single-stranded viral RNAs (TLR8) induced robust production of the Thlpolarizing cytokines TNF-alpha and IL-12 from neonatal antigen-presenting cells (APCs) that substantially exceeds responses induced by TLR-2,-4, or -7 (alone) agonists. TLR8 agonists also effectively induced up-regulation of the costimulatory molecule CD40 on neonatal and adult myelold dendritic cells (DCs). The strong activity of TLR8 agonists correlates with their induction of p38 MAP kinase phosphorylation and with degradation Of I kappa B-alpha in both neonatal and adult monocytes. We conclude that TLR8 agonists are uniquely efficacious in activating costimulatory responses in neonatal APCs and suggest that these agents are promising candidate adjuvants for enhancing immune responses in human newborns.
引用
收藏
页码:1284 / 1290
页数:7
相关论文
共 47 条
[1]  
Adkins B, 2000, Int Rev Immunol, V19, P157, DOI 10.3109/08830180009088503
[2]   Toll-like receptor signalling [J].
Akira, S ;
Takeda, K .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (07) :499-511
[3]  
ANGELONE DF, 2006, PEDIATR RES, V60, P1
[4]  
[Anonymous], INFECT DIS FETUS NEW
[5]   Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[6]   Regulation of IL-12 p40 promoter activity in primary human monocytes:: Roles of NF-κB, CCAAT/enhancer-binding protein β, and PU.1 and identification of a novel repressor element (GA-12) that responds to IL-4 and prostaglandin E2 [J].
Becker, C ;
Wirtz, S ;
Ma, XJ ;
Blessing, M ;
Galle, PR ;
Neurath, MF .
JOURNAL OF IMMUNOLOGY, 2001, 167 (05) :2608-2618
[7]   Defective macrophage function in neonates and its impact on unresponsiveness of neonates to polysaccharide antigens [J].
Chelvarajan, RL ;
Collins, SM ;
Doubinskaia, IE ;
Goes, S ;
Van Willigen, J ;
Flanagan, D ;
de Villiers, WJS ;
Bryson, JS ;
Bondada, S .
JOURNAL OF LEUKOCYTE BIOLOGY, 2004, 75 (06) :982-994
[8]  
Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372
[9]  
COHEN L, 1995, J IMMUNOL, V155, P5337
[10]   Impaired responses to toll-like receptor 4 and toll-like receptor 3 ligands in human cord blood [J].
De Wit, D ;
Tonon, S ;
Olislagers, V ;
Goriely, S ;
Boutriaux, M ;
Goldman, M ;
Willems, F .
JOURNAL OF AUTOIMMUNITY, 2003, 21 (03) :277-281